Singapore, 30 May 2016 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced the appointments of Professor Lai Mei-Shu and Mr Kelvin Sun as Independent Non-Executive Directors, and Dr Jerome Shen as Non-Executive Director.
Professor Lai Mei-Shu (PhD, MPH, MD) is an accomplished researcher and administrator. She is currently Dean of MJ Life, a leading health management centre in Taiwan, where she oversees its operations as well as business development and collaborations. She is also Honorary Professor of Epidemiology and Preventative Medicine at National Taiwan University. A gastroenterologist by training, Professor Lai was previously Deputy Minister at the Department of Health, Taiwan, and served as President & Chief Executive Officer at the Bureau of National Health Insurance, Taiwan.
Mr Kelvin Sun is Founder and President of Saga-Unitek Ventures and has a wealth of experience in board management roles. He is currently Independent Director of public-listed companies, TWipharma (TSE 4180) and Wonderful Hi-Tech (TSE 6190), a Board Member of Taiwan Venture Capital Association and five of Saga-Unitek’s portfolio companies. Kelvin has held senior roles in his professional career, including Senior Officer at Chengxin VC Group; Director at Emerson Electric; and R&D Leader at Prime Optic Fiber.
Dr Jerome Shen (PhD) is President of Allgenesis Biotherapeutics Inc and has over two decades of venture capital experience in the life science and biotech industries. He was an executive member of various venture capital firms including Cheng Xin Ventures and Xinchen Ventures. A chemical engineer by training, Jerome was also previously Secretary General of the Taiwan Biotech Association.
Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals said: “We are delighted to welcome Mei-Shu, Kelvin and Jerome to ASLAN’s Board of Directors. The depth of their expertise in their respective fields are a great asset to our company as we look to grow and strengthen our position in Taiwan and the region.”
Professor Lai Mei-Shu (PhD, MPH, MD) is an accomplished researcher and administrator. She is currently Dean of MJ Life, a leading health management centre in Taiwan, where she oversees its operations as well as business development and collaborations. She is also Honorary Professor of Epidemiology and Preventative Medicine at National Taiwan University. A gastroenterologist by training, Professor Lai was previously Deputy Minister at the Department of Health, Taiwan, and served as President & Chief Executive Officer at the Bureau of National Health Insurance, Taiwan.
Mr Kelvin Sun is Founder and President of Saga-Unitek Ventures and has a wealth of experience in board management roles. He is currently Independent Director of public-listed companies, TWipharma (TSE 4180) and Wonderful Hi-Tech (TSE 6190), a Board Member of Taiwan Venture Capital Association and five of Saga-Unitek’s portfolio companies. Kelvin has held senior roles in his professional career, including Senior Officer at Chengxin VC Group; Director at Emerson Electric; and R&D Leader at Prime Optic Fiber.
Dr Jerome Shen (PhD) is President of Allgenesis Biotherapeutics Inc and has over two decades of venture capital experience in the life science and biotech industries. He was an executive member of various venture capital firms including Cheng Xin Ventures and Xinchen Ventures. A chemical engineer by training, Jerome was also previously Secretary General of the Taiwan Biotech Association.
Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals said: “We are delighted to welcome Mei-Shu, Kelvin and Jerome to ASLAN’s Board of Directors. The depth of their expertise in their respective fields are a great asset to our company as we look to grow and strengthen our position in Taiwan and the region.”
